(Q68548295)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2208578%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

title

Pharmacokinetics of repeated i.v. bolus administration of high doses of r-met-Hu interleukin-2 in advanced cancer patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2208578%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

1 reference

J P Sculier

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2208578%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

J J Body

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2208578%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

N Donnadieu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2208578%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

S Nejai

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2208578%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

F Glibert

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2208578%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

N Raymakers

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2208578%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

M Paesmans

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2208578%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

publication date

1 January 1990

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2208578%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

25 September 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2208578%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2208578%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2208578%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

page(s)

355-358

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2208578%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf02897293

25 September 2019

exact match

0 references

cites work

Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality

1 reference

12 December 2020

A phase I study of recombinant interleukin 2 in melanoma patients. Toxicity and clinical effects.

1 reference

12 December 2020

Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial

1 reference

12 December 2020

Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level

1 reference

12 December 2020

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

1 reference

12 December 2020

Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease

1 reference

12 December 2020

Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

1 reference

12 December 2020

The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2)

1 reference

12 December 2020

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Interleukin-2: inception, impact, and implications

1 reference

12 December 2020

Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02897293

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2208578%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

1 reference